abstract |
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. Further, the pharmaceutical compositions of the present invention can include a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. |